

AD _____

Award Number: W81XWH-04-1-0138

TITLE: Imaging Metastatic Prostate Cancer After Genetic
Manipulation of Transcriptional Memory Regulators EZH2
and EED

PRINCIPAL INVESTIGATOR: Lily Wu, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of California at Los Angeles
Los Angeles, California 90024-1406

REPORT DATE: January 2005

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050727 120

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE January 2005	3. REPORT TYPE AND DATES COVERED Final (1 Jan 2004 - 31 Dec 2004)	
4. TITLE AND SUBTITLE Imaging Metastatic Prostate Cancer After Genetic Manipulation of Transcriptional Memory Regulators EZH2 and EED			5. FUNDING NUMBERS W81XWH-04-1-0138	
6. AUTHOR(S) Lily Wu, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California at Los Angeles Los Angeles, California 90024-1406 <i>E-Mail:</i> lwu@mednet.ucla.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) No abstract provided.				
14. SUBJECT TERMS No subject terms provided.				15. NUMBER OF PAGES 6
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	6

Introduction:

This project is intended to explore the role of polycomb group protein EZH2 and its binding partner EED in metastatic prostate cancer. Both proteins will be introduced and overexpressed independently overexpressed in prostate cancer xenograft models by lentiviral transduction. Concordantly, the effects of reduced EZH2 or EED expression will be evaluated by RNAi technology. The growth and progression of the tumors will be monitored by optical imaging. The hypothesis is that EZH2 serves as a master regulator protein in prostate cancer metastasis; therefore, disruption of the balance between EZH2 and EED will result in a more aggressive disease phenotype. Exploration of the relationship between EZH2 levels and kinetics of dissemination of cancer cells will result in a better understanding of disease progression and appropriate treatment approaches.

Body:

Aim 1: Generation of lentiviral vectors that overexpress EZH2 or EED and that suppress expression by RNA interference (RNAi).

The lentivirus vector to deliver and overexpress EZH2 (pCCL-CMV-EZH2-IRES-EGFP) and the control vector (pCCL-CMV-IRES-EGFP) were constructed and produced. The use of EGFP, a fluorescence gene, rather than the originally proposed luciferase allows us to monitor vector transfection and transduction, and to deduce the expression levels of EZH2 by fluorescence microscopy, making production and evaluation of the vector more rapid and efficient. The luciferase gene to facilitate optical imaging of tumor growth and progression was introduced into cells by co-infection with a separate lentivirus (pCCL-CMV-RL).




Figure 1: Screening of prospective siRNA sequences.

Four unique siRNA sequences were transfected into cells overexpressing EZH2. Cells were harvested and assayed for EZH2 levels at 48 and 72 hours post transduction. NT: Not Transfected with siRNA. Non-Specific: siRNA specific for luciferase. 2.1, 2.2, 2.3, and 2.4 are unique siRNA target sequences. 2.1M, 2.2M, 2.3M, and 2.4M are modified versions of the parent sequence to test for increased effectivity.

pCCL-CMV-EZH2-IRES-EGFP was used to transduce 293T cells, which were then used to screen four unique siRNA sequences. Plasmids encoding the prospective siRNAs were transfected into the EZH2 overexpressing cells, which were then harvested at either 48 or 72 hours. Knockdown of lentiviral EZH2 expression was evaluated by western blot (Figure 1). Transducing cells with the EZH2 lentivirus proved more efficient and provided more reliable results than the original cotransfections (data not shown). Based on these results, siRNA 2.1 was selected for use in the xenograft model experiments. siRNA2.1 is currently being cloned into the lentiviral vector for production of the siRNA lentivirus.

Design and production of the EED lentivirus and EED specific siRNA are ongoing at this time.

Aim 2: Monitor the effects of genetic modifications of PcG genes on metastasis of prostate xenograft by optical imaging.

Prostate cancer xenograft model LAPC9 cells were marked with the pCCL-CMV-RL lentivirus and either pCCL-CMV-EZH2-IRES-EGFP (EZH2 tumors) or pCCL-CMV-IRES-EGFP (control tumors) and implanted in SCID mice. Beginning two weeks after implantation, the mice were imaged to monitor tumor growth and the tumors themselves were measured. In both optical signal (Figure 2) and physical tumor size (data not




Figure 2: Side-by-Side Comparison of EZH2 versus Control Optical Signal at 2 and 4 Weeks.

Animals were imaged for luciferase signal as a means of tracking tumor growth and progression. At week 2 (top), animals with EZH2 overexpressing tumors (left) clearly demonstrate higher signal than animals with Control tumors (right). By week 4 (bottom), however, this inequity has resolved due to slower growth by the EZH2 tumors.

in preliminary experiments (Figure 3). Use of the TetON lentivirus system to manage the level and length of EZH2 expression will permit more control over the stimulus provided to the tumor. In addition, we will be able to more conclusively determine if decline in EZH2 expression was truly responsible for the decrease in tumor growth rate.

shown), the EZH2 group showed an astounding growth advantage over the control group. Therefore, EZH2 overexpression appeared to confer an initial growth advantage in the LAPC9 xenograft model. By week 4, however, the initial advantage conferred by EZH2 overexpression had diminished to such a degree that the control tumors were equal to the EZH2 tumors in both optical signal and size. At the study endpoint (week 7), tumors were removed and analyzed for EZH2 expression by western blot. Interestingly, the EZH2 marked tumors showed no detectable EZH2 expression. This decline is possibly due to silencing of the integrated lentiviral genome or a decrease in CMV promoter activity due to conditions within the tumor. However, the drop in EZH2 expression may correlate with and be responsible for the deceleration in EZH2 tumor growth observed by week 4 of the study.

To attain more control over the expression of EZH2 in the tumor environment, we initiated the construction of a Tet regulated lentiviral expression system. The use of the TetON system will allow EZH2 expression only in the presence of the inducer doxycycline. This system was demonstrated to be highly titratable and controlled




Figure 3: Titration of the TetON system expression of EZH2.

293 cells were cotransduced with the elements of the TetON system in varying ratios and tested for induction with increasing amounts of Doxycycline. Lanes 1-6 are controls. Lanes 7-18 are titrations of the TetON system. Asterisk denotes EZH2 band. Arrow denotes β -actin control for equal loading. A middle non-specific band was detected.

Key Research Accomplishments:

- Construction and generation of pCCL-CMV-EZH2-IRES-EGFP lentiviral vector.
- Successful screening of prospective EZH2 siRNA sequences. Identification of siRNA2.1 as top inducer of RNAi effect.
- Seminal study of effects of EZH2 overexpression in prostate cancer xenograft model, monitored by optical imaging. Preliminary results indicate a growth advantage conferred by EZH2 overexpression.
- Initiation of construction on a TetON lentiviral expression system for EZH2. System is highly regulated and titratable.

Reportable Outcomes:**Abstracts:**

Breanne D. White and Lily Wu. Characterizing the effects of EZH2-overexpression in prostate cancer progression using in vivo optical imaging. AACR Annual Meeting 04/2005

Funding:

Breanne White secured the Predoctoral Cell and Molecular Biology Training Program, UCLA. (07/2004)

Conclusions:

We discovered that EZH2 overexpression in a prostate tumor induced tumor cell proliferation. However, long-term effect of EZH2 cannot be investigated as loss of its expression was selected for in the tumor. Thus, we have created a titratable, tetracycline regulated system to express this important regulatory gene. The regulated expression will enable us to better define the functional role of EZH2 in tumor progression. The knockdown study using stable siRNA expression system is proceeding without difficulty. In the next 6 months, we would be able to accomplish all the proposed tasks of the project. Our intention is to extend this conceptual idea to a comprehensive study of this very interesting polycomb gene, EZH2.